Navigating the Clinical & Regulatory Pathway to Approval in Rare Kidney Disease

• Demonstrating efficacy across multiple endpoints to support regulatory decisionmaking in rare kidney disease
• Designing clinical programs that balance feasibility with the need for robust and clinically meaningful data
• Overcoming challenges associated with small, heterogeneous patient populations in late-stage development

Speakers:

Eli Khankin

Executive Director

Apellis Pharmaceuticals